A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism | JACC: Advances
Release Date: 05/28/2025
JACC Specialty Journals
Audio Summary of the June 2025 Issue by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Terence Quinn.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Meixiang Xiang.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Jian'an Wang.
info_outlineJACC Specialty Journals
Commentary by Dr. Shinya Goto.
info_outlineDarshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.